Research Awards:

    1.  ASH abstract achievement award, ASH Annual Meeting, San Diego, Dec 3-7 2016
    2. Wallace H. Coulter Foundation-ASH (American Society of Hematology) Abstract Achievement Award, ASH Annual Meeting, Dec. 2014, San Francisco, CA, USA.
    3. ASH Abstract Achievement Award, ASH Annual Meeting, Dec. 2013, New Orleans, LA.
    4. European Hematology Association Travel Grant 2013: Annual Meeting, Sweden.
    5. ASH (American Society of Hematology) Travel Award, ASH Annual Meeting, Dec. 2010.
    6. Susan G. Komen / AACR Scholar-in-Training Award 2010: American Association for Cancer Research (AACR) Award, AACR Special Conference “Advances in Cancer Research-From Laboratory to Clinic” at Amman, Jordan, from March 07-10, 2010.
    7. AACR / ITO EN Scholar-in-Training Award 2009: AACR 100TH Annual Meeting—April 18-22, 2009; Colorado, Denver.
    8. Shanghai Education Commission Fellowship (Clinical Hematology): Research/clinical training at Shanghai Jiao-Tong University College of Medicine China in the field of Functional Medical Genomics / Clinical Hematology.
    9. SIES Award 2006: Italian Society of Experimental Hematology (SIES) in IX Congress of this society (September 2006); research paper “Role of Pre-existing BCR-ABL gene ATP-binding domain mutations in outcome of Gleevec therapy in CML”.
    10. PSF Travel Award: Pakistan Science Foundation (PSF) Travel award to participate in VIII Congress of Italian Society of Experimental Hematology (September 2006).
    11. Best Cancer Researcher Award: Awarded by Society of Clinical Oncology Pakistani (SCOP) on occasion of their 10th National and 1st International cancer conference (18th-21st December 2003), for best cancer research article in the field of Leukemia.


Publications:

(Names of society members are highlighted).


  1. Elsafadi M, Manikandan M, Atteya M, Hashmi JA, Iqbal Z, Aldahmash A, Alfayez M, Kassem M, Mahmood A. Characterization of Cellular and Molecular Heterogeneity of Bone Marrow Stromal Cells. Stem Cells Int. 2016;2016:9378081. doi:10.1155/2016/9378081. Epub 2016 Aug 16.
  2. Iqbal Z, Akram AM, Akhtar T, Aleem A, Sabar MF, Aziz Z et al., Novel Compound BCR-ABL Mutations in Late Chronic Phase Imatinib Sensitive CML Patients Are Associated with Progression to Advance Disease Phase. Blood 2016 128:3089 (ASH 2016 Meeting Abstracts). http://www.bloodjournal.org/content/128/22/3089

  3. Al Jamaan K, Al Oraibi S, Saglio G, Iqbal M and Iqbal Z, et al. First Report on Elevated Transcranial Doppler Ultrasound Velocities As First Stroke Risk and Their Association with Hemoglobin F Expression in Saudi Arabian Pediatric Sickle Cell Patients. Blood 2016 128:3665 (ASH 2016 Meeting Abstracts). http://www.bloodjournal.org/content/128/22/3665

  4. Karim S, Kamal MA, Iqbal Z, Ansari SA, Rasool M, Al-Qahtani MH, Damanhouri G, Mirza Z. Global expression studies of schizophrenic brain: A Meta-analysis study linking neurological immune system with psychological disorders. CNS Neurol Disord CNS Neurol Disord Drug Targets. 2016;15(4):477-88.

  5. Aleem, A, Alsaleh K, Aljabry M,3 Aziz S, Iqbal Z,Almomen AK. A comparison of two techniques of preparing bone marrow aspirate slides. JPMA 2016, 66(5): 528-531.

  6. Rasool M, Iqbal Z, Israr S, Saleem S, Gillani Z, Qazi MH, et al. . BAD, a Proapoptotic Protein, Escapes ERK/RSK Phosphorylation in Deguelin and siRNA-Treated HeLa Cells. PLoS One. 2016 Jan 8;11(1):e0145780. doi: 10.1371/journal.pone.0145780. eCollection 2016.

  7. Iqbal Z, Mahmood R, Aleem A. Status of BCR-ABL monitoring in developing countries and need for careful application for automated Xpert BCR-ABL Monitor™ (Cepheid) system in CML patients: Saudi Arabia as an example. Blood (Online), 12/2015; 126(3):5170 E-Letter.. http://www.bloodjournal.org/content/126/23/5170.e-letters. 

  8. Iqbal Z, Khalid K, Akhtar T, Sabir N, Aleem M, Rasool M, et al. High frequency and poor prognosis of late childhood BCR-ABL positive and MLL-AF4 positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan. Mol Diagn Ther. 2015 Oct;19(5):277-87.

  9. Aljamaan K, Aljumah TK, Aloraibi S, Absar M, Iqbal Z. Low Frequency of ETV6-RUNX1 (t 12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with Clinical Parameters and Early Remission. Asian Pac J Cancer Prev. 2015; 16(17):7523-7.

  10. Tahira B, Asif M, Khan S, Hussain A, Shahwani MN, Malik A, Inayatullah S, Iqbal Z, Rasool M. Detection of BCR/ABL Fusion Gene by Hematological and Cytogenetical Analysis in Chronic Myeloid Leukemia Patients in Quetta, Pakistan. Asian Pac J Cancer Prev. 2015; 16(9):3793-7. 2.51 Impact Factor

  11. Shahid M, Sabar MF, Bano I, Rahman Z, Iqbal Z, Fatim Ali SS, Ghani MU, Iqbal M, Husnain T. Sequence variants on 17q21 are associated with the susceptibility of asthma in the population of Lahore, Pakistan. J Asthma. 2015 Jul 23:1-8.

  12. Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M, Sani S, Qazi MH, Kamal MA, Iqbal Z, Hussain A. Assessment of circulating biochemical markers and antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Saudi J Biol Sci. 2015 Jan; 22(1):106-11.

  13. Iqbal Z. Molecular genetic studies on 167 pediatric ALL patients from different areas of Pakistan confirm a low frequency of the favorable prognosis fusion oncogene TEL-AML1 (t 12; 21) in underdeveloped countries of the region. Asian Pac J Cancer Prev. 2014; 15(8):3541-6.

14.              Tayyab M, Khan M, Akhtar T, Iqbal Z, Noor Z, Noor N. Distinct Gene Mutations, their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid Leukemia (AML). J Cancer Sci Ther 2014, 6:337-349. doi: 10.4172/1948-5956.1000292. http://omicsonline.org/open-access/distinct-gene-mutations-their-prognostic-relevance-and-molecularly-targeted-therapies-in-acute-myeloid-leukemia-aml-1948-5956.1000292.pdf

15.              Iqbal Z,  Akhtar T, Akram AM,  Khalid M, Shah IH,  Aleem A, et al. Detection of Compound BCR-ABL Mutations in TKI Resistant CML Patients Including a Novel K245N Mutation Associated with Primary Nilotinib Resistance By Employing a Newly Developed Cost Effective BCR-ABL Sequencing Protocol. Blood 2014: 124 (21): 1810. http://www.bloodjournal.org/content/124/21/1810.

Iqbal Z. A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology. Indian J Hum Genet. 2014 Jan; 20(1):64-8.

Akram A, Akhtar T and Iqbal Z. Survival assessment and Optimization of BCR/ABL-KD amplification protocol for detection of Imatinib resistant mutations in Ph+ Chronic Myeloid Leukemia patients from Pakistan
Gene therapy & molecular biology 02/2014; 16:10. http://www.gtmb.org/volumes/Vol16/2.Akram_et_al_10-29.pdf 

Aleem A, Shakoor Z, Alsaleh K, Algahtani F, Iqbal Z, Al-Momen A. Immunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox. J Coll Physicians Surg Pak. 2014 Jul;24(7):467-71.

Rasool M, Rashid S, Arooj M… Iqbal Z, Gan SH, Kamal MA, Sheikh IA. New possibilities in hepatocellular carcinoma treatment. Anticancer Res. 2014 Apr; 34(4):1563-71.

Rasool M, Malik A, Qazi A, Sheikh I, Manan A, Shaheen S, Iqbal Z et al. Current View From Alzheimer Disease To Type 2 Diabetes Mellitus. CNS & Neurological disorders-Drug Targets 2014 Apr; 13(3):533-42.

Shahbaz S, Akhtar T, Iqbal Z. Optimization of nested RT-PCR for the detection of a common fusion oncogene AML1/ETO of Acute Myeloid Leukemia in Pakistan. Biologica 2014, 60 (2): 255-260. ISSN 2313 – 206X.

  1. Karim S; Ansari SA; Rasool S; Iqbal Z; Sohrab SS; Abuzenadah AM and Al-Qahtani M. Transcriptomics study of neurodegenerative disease: Emphasis on synaptic dysfunction mechanism in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2014;13(7):1202-12.

  2. Alanazi A, Alsalmeh M, Alsomali O, Almurshdi AM, Alabdali A, Al-Sulami M, Al-Nemer A, Al-Qusairy A, Aloraibi S and Iqbal Z. Poor Basic Life Support Awareness among Medical and College of Applied Medical Sciences Students Necessitates the Need for Improvement in Standards of BLS Training and Assessment for Future Health Care Providers. Middle-East Journal of Scientific Research 21 (5): 848-854, 2014. DOI: 10.5829/idosi.mejsr.2014.21.05.82335 http://www.idosi.org/mejsr/mejsr21%285%2914/21.pdf

  3. Alanazi A, Al Moamary M, Ismaeli T, Alanazi AN, Olayan LH, Alanazi AM, Abu Nurah HY, Iqbal Z and Qureshi S. The Reliability of the Arabic Version of the Asthma Knowledge Questionnaire and Assessment of the Level of Asthma Awareness among Parents of Children with Asthma in Saudi Arabia. Middle-East Journal of Scientific Research 20(4):412-418, 2014. DOI: 10.5829/idosi.mejsr.2014.20.04.82258. http://www.idosi.org/mejsr/mejsr20%284%2914/2.pdf

  4. Iqbal Z, Aleem A, Iqbal M,…, Khalid AM et al. Detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic phase chronic myeloid leukemia patients is associated with imatinib resistance: First large-scale study with implication in post-Imatinib era. PLoS ONE 2013; 8(2): e55717. doi:10.1371/journal.pone.0055717.

  5. Aleem A, Anjum F, Algahtani F, Iqbal Z, Alsaleh K.  Clofarabine in the treatment of elderly patients with acute myeloid leukemia. Asian Pac J Cancer Prev. 2013; 14(2):1089-92.

  6. Awan T, Iqbal Z, Aleem A, Sabir N, Absar M, Rasool M et al, . Five Most Common Prognostically Important Fusion Oncogenes are Detected in the Majority of Pakistani Pediatric Acute Lymphoblastic Leukemia Patients and are Strongly Associated with Disease Biology and Treatment Outcome.  Asian Pac J Cancer Prev. 2012; 13(11):5469-5475.

  7. Iqbal Z. Molecular Hematology in Leukemia Biology and Treatment: Past, present and future. J. App. Hematol. 2012 October; 3(2):55-61.

  8. Begum M, Karim S, Malik A, Khurshid R, Asif M, Salim A, Nagra SA, Zaheer A, Iqbal Z, Abuzenadah AM, Alqahtani MH, Rasool M.CA 15-3 (Mucin-1) and Physiological Characteristics of Breast Cancer from Lahore, Pakistan. Asian Pac J Cancer Prev. 2012; 13(10):5257-61.

  9. Aleem A, Al Diab AR, Alsaleh K, Algahtani F, Alsaeed E, Iqbal Z, El-Sherkawy MS. Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients. Asian Pac J Cancer Prev., 2012; 13(4):1311-5.

  10. Sabir N, Iqbal Z, Aleem A, Awan T, Naeem T, Asad S, et al. Prognostically Significant Fusion Oncogenes in Pakistani Patients with Adult Acute Lymphoblastic Leukemia and Their Association with Disease Biology and Outcome. Asian Pac J Cancer Prev., 2012;13(7):3349-55..

  11. Iqbal Z, Manzoor F, Iqbal M, Ali S, Sheikh N, Khan M; Aleem A , Tanveer A. Frequency of BCR-ABL Fusion Oncogene Splice Variants Associated with Chronic Myeloid Leukemia (CML). Journal of Cancer Therapy, 2011, 2, 176-180.

  12. Malik S, Hanif A, Khokher S, Iqbal Z, Rana S, Imran M, Bilal M, Arslan M. Association of genetic and non-genetic risk factors with specific BRCA mutation positive breast cancers in some Pakistani females. Pak J Physiol 2009;5(1): 51-57.

  13. Iqbal Z., Iqbal M. and Akhtar T. Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukaemia (ALL) patients reflects ethnic differences in molecular genetics of ALL.J. Paed. Hemat. Oncol., 2007, 29 (8): 585.

  14. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Ahmad M. Khalid.  Case study of primary Imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia. Therapy (2004), 1(2): 249-254.

  15. Iqbal Z., Siddiqui R.T.  and Qureshi J. A. Two different point mutations in BCR-ABL gene ATP-binding domain conferring primary Imatinib resistance in a chronic myeloid leukemia (CML) patient: a case report. Biol. Proced. Online 2004; 6(1): 144-148.

  16. Zafar Iqbal, Ijaz Shah, Aamer Aleem, Mubashar Naqvi, Ammara Tahir, et al. Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance. Nature Precedings Online. 28 November 2011. http://precedings.nature.com/documents/6645/version/1.

  17. Iqbal Z., Siddiqui R. T.  and Qureshi J. A. Detection of point mutations conferring acquired and natural Gleevec resistance in chronic myeloid leukemia patients. J. Pak. Med. Assoc., December 2003, 53(12): 9-10.

  18. Tanveer, A., and Iqbal, Z. 2000. Isolation of Bacillus sp., from water samples collected from snail habitats and its evaluation as biomolluscicide. Punjab Univ. J. Zool., 15: 171-181.

  19. Iqbal Z., Muqaddas A. and Tanveer A. Evaluation of  Bacillus sp. as biomolluscicide against freshwater snail Lymnaea acuminata. Punj. Univ. J. Zool., 2000, 9: 50-57.

  20. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on bacteria isolated from freshwater physid snail and their evaluation as snail controlling agent. Acta Scientia, January 1999,  9: 58-68.

  21. Iqbal Z., Muqaddas A. and Tanveer A. Some studies on  pathogenic bacteria isolated from freshwater lymnaid snails and their evaluation as snail controlling agent. Acta Scientia, January 1999,  9: 69-78.

  22. Iqbal Z, Akram MA · Akhtar T, Khalid M, Zeba A· Aleem A, et al. High Frequencies of Compound BCR-ABL Mutations and Their Association with Imatinib Resistant, Disease Progression and Late Chronic Phase Disease in Pakistani Chronic Myeloid Leukemia Patients Necessitate the Inclusion of Molecular Testing in Routine Clinical Settings . Blood 12/2015; 126(23):5167. · 10.45 Impact Factor. https://www.researchgate.net/profile/Zafar_Iqbal53/contributions

  23. Aamer A, Al Wusibai F, AlSaleh K, Alqahtani F, Iqbal Z,  Chaudhri NA,  Al-Momen AK. Multiple Brain Hemorrhages on Presentation in a Patient with Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in Leukemia Proliferation. Blood 12/2015; 126(23):5153. · 10.45 Impact Factor

  24. Aljamaan K, Aljumah TK, Aloraibi S, Absar M, Iqbal Z. Low Representation of ETV6-RUNX1 Fusion Oncogene in Pediatric Acute Lymphoblastic Leukemia Patients from Saudi Arabia and Strong Association with Clinical Response to Day-14 of Remission Induction Therapy . Blood 12/2015 (ASH Meeting Abstracts); 126(23):4987. · 10.45 Impact Factor

  25. Zafar Iqbal, Tashfin Awan, Tanveer Akhtar, Aleem Aamer, Noreen Sabir, Muhammad Absar, Iqbal Mudassar, Ahmad Mukhtar Khalid, Giuseppe Saglio, Mahmood Rasool, and Akhtar Hussain. High Frequency Of BCR-ABL/t(22;9) Translocation As Detected By RT-PCR and Interphase FISH In Pediatric B-Cell ALL Patients Identifies The Need For Immediate Inclusion Of Tyrosine Kinase Inhibitors In Pediatric ALL Treatment Protocols. Blood 2013 122:3908.

  26. Zafar Iqbal, Saba Shahzadi, Tanveer Akhtar, Aleem Aamer, Ahmad Mukhtar Khalid, and Iqbal Mudassar. BCR-ABL Splice Variants In Three Phases Of CML: Association With Disease Biology and Response To Imatinib. Blood 2013 122:5191.

  27. Zafar Iqbal, Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad Sultan, et al. Characterization of Common Fusion Oncogenes As Prognostic Molecular Identities in Adult Acute Lymphoblastic Leukemia Identifies the Need for Genetic Testing At Presentation, Molecular Prognostication and Differential Treatment. Blood (ASH Annual Meeting Abstracts) 120 (21): 5115. (Impact Factor 9.90)

  28. Zafar Iqbal, Sabir Noreen, Aleem Aamer, Awan Tashfeen, Tahir Naeem, Asad Sultan, et al. Detection of Five Common Fusion Oncogenes in Pakistani Children with Acute Lymphoblastic Leukemia and Their Association with Clinical Pattern and Treatment Outcome. Blood (ASH Annual Meeting Abstracts) 120 (21): 5124. (Impact Factor 9.90)

  29. Zafar Iqbal, Tashfeen Awan, Mudassar Iqbal, Noreen Sabir. High frequency of BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as revealed by RT-PCR and interphase FISH: association with disease biology and treatment outcome. J Clin Oncol 30, 2012 (suppl): 6612 (Proceedings of 2012 Annual Meeting of American Society of Clinical Oncology, Chicago, Illinois, USA). (Impact Factor 18.372)

  30. Zafar Iqbal, Mudassar Iqbal, Tanveer Akhtar, Mubashar Iqbal Naqvi, Ammara H Tahir, Tariq Jameel Gill,  et al . Presence of Prior-to-Treatment BCR-ABL Mutations In CD34+CD38- Stem Cells of Newly Diagnosed Chronic Phase CML Patients and Their Correlation with Imatinib Resistance: Implications of Cancer Pharmacogenomics and Pre-Therapeutic Genetic Testing In Personalized Treatment of BCR-ABL+ Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (21): 2278. (Impact Factor 9.90)

  31. Z Iqbal, N Sabir, M Iqbal, A Tashfeen, A Aleem, A Mukhtar Khalid, T Akhtar. Poor Outcome Of TCF3-PBX1 Despite Its Association With Favorable Risk Factors Stresses The Need For Intensified Remission Therapy For Patients Of This Genetic Subgroup In Adult Acute Lymphoid Leukemia. Haematologica 2013; 98(s1): 264. EHA Abstract n. P625 (Impact Factor 6.424).

  32. Z Iqbal, A Tashfeen, M Iqbal, N Sabir, A Aleem, A Mukhtar Khalid, T Akhtar. High Frequency of BCR-ABL In Pediatric Acute Lymphoid leukemia with Poor Outcome Identifies The Immediate Need For Incorporation of Imatinib And Other Tyrosine Kinase Inhibitors In Treatment Protocols. Haematologica 2013; 98(s1): 268. EHA Abstract n. P635 (Impact Factor 6.424).

  33. Iqbal Z, Li-Juan Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer A.. First comprehensive study on pre-existing BCR-ABL KD mutations and subsequent Imatinib resistance in CML patients: Value of pre-treatment genetic testing and implication in patient-tailored therapy of Leukaemia. Annals of Oncology, May 2008, 19 (3): 40-41.

  34. Iqbal Z., Baig S.M., Aziz Z. and Akhtar T. Clinical significance of pre-existing  BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML) patients: implication in prognosis and Imatinib follow-up studies. Annals of Oncology, 2007, 18(Supp. 4): iv4.

  35. Iqbal Z. High frequency of pre-existing BCR-ABL gene ATP-binding domain mutations associated with natural Gleevec resistance in chronic myeloid leukemia (CML) patients. Haematologica, 2006; 91(s3): 3.

  36. Iqbal Z. Frequency of chromosomal abnormalities and corresponding fusion oncogenes in acute lymphoblastic leukemia (ALL) patients of Pakistan and its implication in differential diagnosis and prognosis of leukemia.  Haematologica, 2006; 91(s3):65.

  37. Iqbal Z. Co-existence of fusion transcripts SIL-TAL1 and BCR-ABL in a paediatric acute lymphoblastic leukaemia (ALL) patient. Haematologica, 2006; 91(s3):6.

  38. Iqbal Z and Tanveer A. Detection of double fusion transcripts/ oncogenes (BCR-ABL, SIL-TAL1) in childhood acute lymphoblastic leukaemia (ALL). Haematologica, 2006; 91(s3):68.

  39. Iqbal Z and Tanveer A. A comprehensive analysis of pre-existing BCR-ABL gene ATP-binding domain mutations associated with natural Gleevec resistance in chronic myeloid leukemia (CML) patients. Haematologica, 2006; 91(s3):93.

  40. Iqbal Z and Tanveer A. First report of co-existence of double fusion transcripts (BCR-ABL and E2A-PBX1) in t-cell acute lymphoblastic leukaemia (ALL).  Haematologica, 2006; 91(s3):68.

  41. Iqbal Z. Eradication of Imatinib-resistance-conferring, pre-existing BCR-ABL ATP-binding domain mutant clones by sustained interferon therapy in CML patients.  Haematologica, 2006; 91(s3):97

  42. Iqbal Z and Tanveer A. Incidence of different fusion oncogenes in acute lymphoblastic leukemia (ALL) patients from Pakistan: possible implication in differential diagnosis, prognosis, treatment and management of ALL. Haematologica, 2006; 91(s3):64.

  43. Iqbal Z. Detection of ring chromosome 21 and Philadelphia chromosome (t 9:22) in a chronic phase CML patient and its response to interferon and Imatinib treatments.  Haematologica, 2006; 91(s3):99.

  44. Iqbal Z and Baig SM. Optimization of simple PCR assay for detection of Globin gene deletions in alpha-thalassemia patients.  Haematologica, 2006; 91(s3): 136.

  45. Iqbal Z. Detection of BCR-ABL ATP-binding domain mutations in Imatinib resistance CML patient who relapsed after bone marrow transplant.  Haematologica, 2006; 91(s3): 139.

  46. Iqbal Z, Aziz Z and Tanveer A. Clinical and molecular biological studies on susceptibility and resistance to Imatinib in Pakistani CML patients: first comprehensive report from South-East Asia. Haematologica, 2006; 91(s3):98.

     Iqbal Z and Tanveer A. High incidence of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukaemia (ALL) patients reflects ethnic differences in molecular genetics of ALL. Haematologica, 2006; 91(s3):65.

  47. Iqbal Z, Abid Sohail Taj and Tanveer a. Studies on post bone marrow transplant (post-BMT) Imatinib resistance in a chronic myeloid leukaemia (CML) patient.  Haematologica, 2006; 91(s3): 139.

  48. Iqbal Z, Aziz Z, Shah IH and Tanveer A. Interferon therapy prior to Imatinib can eradicate pre-existing BCR-ABL ATP-binding domain mutations conferring natural Imatinib resistance in CML patients. Haematologica, 2006; 91(s3):96

  49. Iqbal Z, Aziz Z, Shah IH, Khalid M and Tanveer A. First report of ring chromosome 21 and Philadelphia chromosome (BCR-ABL fusion gene) in a 40 years old CML patient resistant to Hydroxyurea: response to interferon and Imatinib. Haematologica, 2006; 91(s3):97.

  50. Iqbal Z. Case report of co-existence of double fusion transcripts (BCR-ABL, E2A-PBX1) in T-cell acute lymphoblastic leukaemia (ALL). Haematologica, 2006; 91(s3):64.

  51. Siddiqui R. T., Qureshi J. A. and Iqbal Z. Development of quantitative competitive reverse  transcriptase PCR (QC-RT-PCR) for detection of minimal residual  disease (MRD) and monitoring anti-leukaemic therapy response in  philadelphia chromosome positive leukemia. Haematologica 2004,  89 (suppl.n.6):94.

  52. Iqbal Z., Aziz Z., Siddiqui R.T., Qureshi J. A. and Khalid A.M. first report of multiple point mutations in BCR-ABL gene ATP-binding domain conferring primary Imatinib resistance in chronic myeloid leukemia patient. Haematologica 2004,  89 (suppl.n.6):97.

  53. Zafar Iqbal; Akhtar Tanveer; Shahid Mahmood Baig; Zeba Aziz; Mudassar Iqbal; et al. T315I and M351T are the most frequent prior-to-Imatinib BCR-ABL kinase domain mutations in chronic phase CML patients and lead to natural Imatinib resistance. In: Online Proceedings of Second AACR (American Association for Cancer Research)-Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, March 7-10, 2010, King Hussein Bin Talal Convention Center, Dead Sea, Jordan.

  54. Zafar Iqbal, Akhtar Tanveer, Mudassar Iqbal, Muhammad Ferhan, Shahid M. Baig, Mubashar Iqbal Naqvi, et al. First comprehensive report of strong interplay of genetic and environmental factors as well as high degree of ethnic and geographical variations in biology of Leukemia as manifested by frequencies of common fusion oncogenes of prognostic significance associated with different Leukemic subtypes in Pakistani population. In: Online Proceedings of AACR (American Association for Cancer Research) 100TH Annual Meeting—April 18-22, 2009; Colorado, Denver.

  55. Zafar Iqbal, Zhao LiJuan, Shahid Baig, Zeba Aziz, Mudassar Iqbal, Ahmad Khalid, and Tanveer Akhtar. Significance of pretherapeutic genetic testing in patient-tailored therapy of leukemia as manifested by correlation of pre-Imatinib BCR-ABL ATP-binding domain mutations and natural Imatinib resistance in CML patients. In: Online proceedings of AACR (American Association for Cancer Research) Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008; Monterey, CA.

  56. Iqbal Z, Baig SM, Aziz Z, Shah IH, Khalid M, Iqbal M and Tanveer A Interferon prior to Imatinib therapy eradicates pre-existing BCR-ABL ATP-binding domain mutations conferring natural Imatinib resistance and leads to more sustained/durable molecular response in chronic myeloid leukaemia. In: Proceedings of, 6th Internal Symposium on Targeted Anti-cancer Therapies (TAT) 2008, Bethesda USA, p. 39.

  57. Iqbal Z., Baig S.M., Aziz Z., Akhtar T. Clinical significance of pre-existing BCR-ABL gene ATP-binding domain mutations in chronic myeloid leukemia (CML) patients: implication in prognosis and Imatinib follow-up studies. In: Proceedings of 5th International Symposium on Targeted Anticancer Therapies (TAT Congress), Amsterdam, March 8-10, 2007, p.59.

  58. Iqbal Z. Siddiqui R.T., Qureshi J. A. and Tanveer A and Zeba Aziz. Unraveling pharmacogenomic basis of primary Imatinib resistance: first report of multiple point mutations in BCR-ABL gene ATP-binding domain conferring primary Imatinib resistance in a ph chromosome positive chronic myeloid leukemia (CML) patient. In: Proceedings of International Conference on Tumor Progression and Therapeutic resistance, Philadelphia USA, November 8-9, 2004, pp: 56-5.





GENEBANK (Nucleotide / NCBI) submissions / Citations:

DNA sequences of Hepatitis B Virus (HBV) surface antigen gene (HBsAg) were submitted to GeneBank (NCBI Core Nucleotide) in 2001-2002. This was a part of M.Phil. research. GeneBank database sequences’ IDs are:

Ø  v AY168835-45 (11 sequences)

Ø  v AF388661-8 (08 sequences)

MS/MPhil and PhD  Research Supervision in Molecular Medical Hematology:

Completed:

Ø  PhD Thesis, supervised at University of the Punjab Lahore, Pakistan, 2014.    

1)      Tashfeen Awan, Hematology / Genetics: PCR-based analysis of prognostically important fusion oncogenes in Pakistani pediatric acute lymphoblastic leukemia patients and their association with disease biology and treatment outcome

2)      Noreen Sabir, Hematology / Genetics: PCR-based analysis of prognostically important fusion oncogenes in Pakistani pediatric acute lymphoblastic leukemia patients and their association with disease biology and treatment outcome.

3)      Afia Akram (Hematology / Genetics): BCR-ABL mutations associated with imatinib resistance in Pakistani Chronic Myeloid Leukemia.

4)    Sana Shahbaz: Molecular Genetic studies of acute myeloid leukemia in Pakistan.

  MS/MPhil (University of The Punjab, Lahore) (Cancer Pharmaco-genomics)    5

Ø  In Process (University of the Punjab Lahore Pakistan):

·                     One Post-doctoral Fellow (Molecular Basis of Drug Resistance in Leukemia)

·                      7 PhDs (Molecular Genetics of Hematological Neoplasms and Breast Cancer)

·                      One MS/MPhil (Genetics of Nilotinib resistance in Ph+ Leukemia)

Make a free website with Yola